[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
Submission ::
Ethics::
Registration::
Contact us::
Site Facilities::
::
Impact Factor
Impact Factor 2022: 1.9
5-Year Impact Factor: 2.2
Cite Score 2022: 3.9
SJR 2022: 0.447
SNIP 2022: 0.538

 
..
Publication Fee
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 12, Issue 2 (Int J Mol Cell Med 2023) ::
Int J Mol Cell Med 2023, 12(2): 172-210 Back to browse issues page
Early Diagnosis of Alzheimer’s Disease with Blood Test; Tempting but Challenging
Fakhrossadat Farvadi1 , Fatemeh Hashemi2 , Azadeh Amini3 , Molood Alsadat Vakilinezhad4 , Mohammad Javad Raee 5
1- Center for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz, Iran.
2- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, the University of Newcastle, Newcastle, Australia.
3- Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran.
4- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran
5- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran. , raeemohammadjavad@gmail.com
Abstract:   (507 Views)
The increasing prevalence of Alzheimer’s disease (AD) has led to a health crisis. According to official statistics, more than 55 million people globally have AD or other types of dementia, making it the sixth leading cause of death. It is still difficult to diagnose AD and there is no definitive diagnosis yet; post-mortem autopsy is still the only definite method. Moreover, clinical manifestations occur very late in the course of disease progression; therefore, profound irreversible changes have already occurred when the disease manifests. Studies have shown that in the preclinical stage of AD, changes in some biomarkers are measurable prior to any neurological damage or other symptoms. Hence, creating a reliable, fast, and affordable method capable of detecting AD in early stage has attracted the most attention. Seeking clinically applicable, inexpensive, less invasive, and much more easily accessible biomarkers for early diagnosis of AD, blood-based biomarkers (BBBs) seem to be an ideal option. This review is an inclusive report of BBBs that have been shown to be altered in the course of AD progression. The aim of this report is to provide comprehensive insight into the research status of early detection of AD based on BBBs.
Keywords: Alzheimer’s disease, blood-based biomarker, early diagnosis, multiplexing
Full-Text [PDF 949 kb]   (223 Downloads)    
Type of Study: Review | Subject: Biomarkers (diagnosis & treatment)
Received: 2022/12/3 | Accepted: 2023/12/13 | Published: 2024/01/16
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farvadi F, Hashemi F, Amini A, Vakilinezhad M A, Raee M J. Early Diagnosis of Alzheimer’s Disease with Blood Test; Tempting but Challenging. Int J Mol Cell Med 2023; 12 (2) :172-210
URL: http://ijmcmed.org/article-1-2056-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 12, Issue 2 (Int J Mol Cell Med 2023) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.05 seconds with 38 queries by YEKTAWEB 4652